Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
Cerluten6 residuesAEDPRGEach bubble = one amino acid. Size = residue mass. Color = chemical class.Also known as: Cytomax A-5, A-5 brain bioregulator, cerebral cortex peptide complex
Forty-eight patients. One open-label study. That is the entire human clinical record for Cerluten, a polypeptide extract from young calf cerebral cortex developed by Vladimir Khavinson in St. Petersburg. The 2003-2004 trial reported positive clinical outcomes in 64.6% of participants with TBI sequelae, post-stroke conditions, and vascular encephalopathy. Those numbers come from the same institution that sells the product. Cerluten sits in the Khavinson bioregulator family as an oral capsule option for CNS support, most often used between injectable Cortexin or Cerebrolysin courses by practitioners familiar with Russian peptide protocols.
Cerluten (Cytomax A-5) is a polypeptide complex extracted from calf cerebral cortex, containing low-molecular-weight peptides under 10,000 Da. The only clinical trial ever run on it showed a 64.6% positive outcome rate across 48 patients with traumatic brain injury sequelae, post-stroke states, and vascular encephalopathy at the St. Petersburg Institute of Bioregulation and Gerontology between 2003 and 2004 [1]. The extract contains low-molecular-weight peptides under 10,000 Da. Glutamic acid, aspartic acid, alanine, leucine, valine, isoleucine, proline, and serine make up the amino acid profile. Component peptides Glu-Asp-Arg and Lys-Glu-Asp stimulated serotonin expression in aging brain cortex cells in vitro by regulating the 5-tryptophan hydroxylase gene [2]. Each capsule holds 10 mg of active peptide complex. Real-world use follows Khavinson Institute protocols: 20-40 mg per day for 10-30 day courses, repeated two to three times per year. Community data is thin. Fewer than 50 documented user reports exist across all platforms. Those who do report benefits describe subtle cognitive clarity and improved sleep, but consistently rank Cerluten below injectable Cortexin and Cerebrolysin for strength of effect. The honest assessment: all published clinical data comes from a single institution, the same one that developed and commercializes the product. No randomized controlled trial exists. No independent replication has been published. No formal pharmacokinetic studies have been conducted. Cerluten is classified as a dietary supplement in Russia, not a registered pharmaceutical.
Brain-derived short peptides small enough to pass through cell membranes and the nuclear envelope. That is the proposed starting point for how Cerluten works. Once inside the nucleus, these peptides are thought to interact directly with DNA and chromatin structures, influencing gene transcription without changing the underlying DNA sequence. The best molecular data comes from studying isolated component peptides rather than the full extract. Glu-Asp-Arg and Lys-Glu-Asp stimulated serotonin expression in aging brain cortex cell cultures by regulating the 5-tryptophan hydroxylase gene through complementary binding to a specific CCTGCC nucleotide sequence [2]. This points to an epigenetic mechanism where short peptides can selectively activate gene transcription. At the chromatin level, brain-derived short peptides have triggered selective deheterochromatinization in preclinical models [3]. That process may reactivate genes silenced during aging. The complex is also proposed to reduce neuronal apoptosis through oxidative stress pathway modulation and to balance neuroinflammatory responses. One important distinction: most published molecular work used synthetic peptides like Cortagen (Ala-Glu-Asp-Pro), not the full Cerluten polypeptide mixture. Whether the crude extract produces the same effects as isolated sequences in a living human brain remains unconfirmed.
Single open-label study (n=48, developer-conducted, St. Petersburg Institute, 2003-2004) reported 64.6% positive outcomes in CNS patients (TBI sequelae, post-stroke, vascular encephalopathy), with improvements in memory, headache, emotional balance, and sleep. In vitro data shows component peptides (Glu-Asp-Arg, Lys-Glu-Asp) stimulate serotonin expression in aging brain cortex cells via 5-tryptophan hydroxylase gene regulation. No RCT, no blinding, no independent replication published.
Khavinson VKh et al. (PMID 24738258): open-label study, 48 CNS patients, 64.6% positive outcomes; in vitro serotonin stimulation data (PMID 24909721)
All clinical data from a single institution that developed and commercialized the product. No RCT, no blinding, no randomization, no independent replication. No formal PK/PD studies. No published human safety trials beyond the single 48-patient cohort.
Subtle cognitive and sleep benefits reported; consistently characterized as weaker than Cortexin (injectable) or Cerebrolysin. Community data is extremely sparse: fewer than 50 documented user accounts across all platforms.
Published institutional science exists (single open-label study + in vitro data) but community presence is near-zero. No meaningful community protocol data exists to compare against or diverge from. Classification reflects scientific publication without independent community validation.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 20mg | Daily |
| Moderate | 40mg | Daily |
| Aggressive | 40mg | Daily |
Cerluten comes as oral capsules, 10 mg each. No reconstitution math here because there's no vial to mix. That makes this one of the simplest peptides to actually use. Standard Khavinson protocol: 2 capsules (20 mg) twice daily for 30 days. That runs through 120 capsules per course. At current pricing, a 60-capsule box from RuPharma costs about $156, so a full standard course at 40 mg per day will set you back roughly $312 for 120 caps. CosmicNootropic sells 20-cap boxes for $30-40, which is a better per-cap price if you're trying a mini-course first. The mini-course option is 2 capsules once daily for 10 days. That's 20 capsules total, a reasonable way to test tolerance before committing to the full protocol. Timing matters: take capsules 15-30 minutes before meals with water. Store at room temperature (15-25 degrees Celsius) away from light and moisture. No refrigeration needed. One thing most beginners miss: Cerluten is considerably weaker than Cortexin (the injectable version from the same source material). If you're coming from Cerebrolysin or Cortexin and expecting similar intensity, recalibrate your expectations downward.
Standard Khavinson bioregulator protocol: 10-30 day courses taken 2-3 times per year with at least 3-month intervals between courses. For acute conditions, shorter 10-20 day courses with 2-3 capsules daily may be used. Some practitioners suggest pairing with Pinealon for combined CNS support.
The Khavinson bioregulator model posits that short peptide courses induce tissue-specific epigenetic gene expression changes that persist for months after active dosing ends. Long rest intervals (3–6 months) are built into protocols based on the premise that repeated short courses maintain beneficial gene expression without continuous compound exposure. This differs from receptor-desensitization or hormonal-axis-recovery cycling: there is no documented receptor tolerance or axis suppression with Cerluten. Rest period duration is institutionally derived, not symptom-driven.
Or use the universal Peptide Calculator for any peptide.
Expected: Subtle improvements in mental clarity and sleep quality by end of course; epigenetic effects proposed to persist several months post-course
Monitor: No blood biomarkers correlate with response. Track subjective cognitive metrics (memory, focus, sleep quality) at baseline and end of course.
Mini-course: 20 mg per day for 10 days. Standard course: 40 mg per day for 30 days. Intensive: 40 mg per day for 10-20 days under physician supervision.
For the standard course, take 2 capsules (20 mg total) in the morning, 15-30 minutes before breakfast with a full glass of water.
Take a second dose of 2 capsules (20 mg) in the evening, 15-30 minutes before dinner. Total daily intake: 4 capsules, 40 mg.
For the mini-course, take 2 capsules (20 mg) once daily before breakfast. Skip the evening dose.
Do not extend beyond 30 days per course.
After completing the course, wait at least 3 months before repeating. Most practitioners run 2 courses per year.
Note sleep quality, focus, memory, headache frequency, and mood. Compare at day 15 and at course completion.
Store capsules at 15-25 degrees Celsius in original packaging. Keep away from direct sunlight and moisture. No refrigeration required.
Recognized Khavinson CNS bioregulator combination. Pinealon targets pineal/hypothalamic function; Cerluten targets cerebral cortex. Complementary tissue specificity within the Khavinson bioregulator framework.
Concurrent or alternating 30-day courses, 2x/year
Recognized combination in Khavinson bioregulator community. Cerebrolysin provides an injectable course with a larger evidence base; Cerluten serves as oral maintenance between injection courses.
Cerebrolysin injection course followed by Cerluten oral maintenance
Related brain-cortex-derived bioregulator (synthetic tetrapeptide Ala-Glu-Asp-Pro). Shares mechanistic rationale of cerebral cortex tissue-specific gene regulation. Some practitioners use both in combined CNS support protocols.
Cognitive enhancement stack. Semax (ACTH 4-7 analog) has faster-acting acute cognitive effects; Cerluten proposed for longer-term epigenetic remodeling. Complementary timescales of action.
Component peptides (Glu-Asp-Arg, Lys-Glu-Asp) demonstrated stimulation of serotonin expression in brain cortex cells in vitro (PMID 24909721). Theoretical additive serotonergic effect with serotonin-modulating medications. No human interaction data published, but mechanism is pharmacologically plausible.
Pricing updated 2026-04-09
The most important thing to know about Cerluten's safety profile: it barely exists. No controlled safety trial has ever been published. No formal toxicology study. No drug interaction assessment. No reproductive toxicity data. The total documented human safety record is a single 48-patient open-label study. In that study, no adverse effects, toxic reactions, or allergic responses were reported [1]. That sounds reassuring until you consider the sample size and the absence of systematic adverse event monitoring. Because Cerluten is a polypeptide complex derived from bovine cerebral cortex, several theoretical concerns apply. Individual hypersensitivity reactions are possible, particularly in anyone with known sensitivity to bovine-derived products. Mild gastrointestinal discomfort could occur given the oral administration route, though this hasn't been specifically documented. The prion question comes up frequently. Source calves are under 12 months old, which falls within the pre-prion-accumulation window. Manufacturing uses ultrafiltration below 15 kDa, and infectious PrPSc protein is 27-30 kDa. Russia has never had a major BSE outbreak. These factors substantially reduce the theoretical risk, but independent Cerluten-specific prion testing has not been published. Cortexin has a published negative immunoblot; Cerluten does not. Batch-to-batch variability is an inherent concern with crude biological extracts. Unlike synthetic peptides with defined sequences, the exact composition of each Cerluten batch can vary. No independent purity or potency testing has been published for commercially available products. The serotonin modulation data [2] raises a practical concern. Component peptides stimulated serotonin expression in vitro. Anyone taking SSRIs, SNRIs, or MAOIs should exercise caution. No human interaction data exists, but the mechanism is pharmacologically plausible. Discuss with a physician before combining. Pregnancy and breastfeeding: no safety data exists. Do not use. Children under 18: insufficient pediatric data. Active malignancy: the proposed gene expression modulation mechanism creates an unfavorable risk-benefit calculation, even though harm has not been documented. Stop use and consult a physician if you experience any allergic reaction, unexpected neurological symptoms, or gastrointestinal distress that persists beyond the first few days of a course.
Verify Cerluten dosing and safety with a second opinion
Crude polypeptide extract from bovine cerebral cortex with theoretical (mitigated) prion risk, inherent batch-to-batch variability as a complex biological extract, no FDA manufacturing oversight, and no independent purity or potency testing published for commercially available products.
| Test | When | Target |
|---|---|---|
| CBC with differential | Baseline + after each 10-day course | — |
| Comprehensive metabolic panel | Baseline + after first course | — |
| Cognitive assessment (MoCA or equivalent) | Baseline + every 6 months | — |
Monitor for immune modulation effects from bioregulator peptides
Screen hepatic and renal function with oral peptide supplementation
Track neuroprotective endpoints: primary use case for Cerluten
No well-documented acute effects. Based on the broader bioregulator model, gene expression changes may begin within the first week. Some users anecdotally report subtle improvements in sleep quality.
Continued proposed gene modulation. In the open-label clinical study, early improvements in headache intensity and emotional balance were noted during the treatment course.
Full course completion. Clinical observations suggest peak improvements in memory, cognitive function, and overall neurological status toward the end of the 30-day course.
Effects from epigenetic remodeling and gene expression changes are proposed to persist beyond the active dosing period. The bioregulator model suggests sustained activity for several months, which is why courses are repeated only 2-3 times per year.
Days 1 through 7: Don't expect fireworks. No documented acute effects exist at standard doses. The bioregulator model predicts gene expression changes may begin during this window, but no pharmacokinetic data confirms it for Cerluten specifically. Some users on Longecity report subtle sleep quality improvement within the first week. Most report nothing noticeable. Days 8 through 14: The open-label study noted early improvements in headache intensity and emotional balance during the second week. Community reports track similarly, with continued subtle sleep benefits and mild cognitive clarity. Effects remain noticeably weaker than what users report with faster-acting peptides like Semax or Selank. Days 15 through 30: This is where the study data gets interesting. The 48-patient cohort showed peak improvements in memory, cognitive function, and overall neurological status toward the end of the 30-day course, with 64.6% showing positive outcomes. Community users who do report benefit describe it primarily as improved sleep and mild cognitive clarity. The word "subtle" appears in nearly every user report. Weeks 4 through 16 (post-course): The Khavinson bioregulator model holds that epigenetic gene expression changes persist for months after you stop taking the capsules. That's the rationale behind the long 3-6 month rest period between courses. Mechanism data supporting this exists for related synthetic peptides like Cortagen and Epitalon, but hasn't been documented specifically for Cerluten's full polypeptide mixture. Community data on post-course persistence is insufficient to draw conclusions.
Bioregulator model predicts gene expression changes may begin within the first week, but no PK studies document this timeline for Cerluten specifically.
Some users report subtle sleep quality improvement within the first week. Most report no noticeable acute effects.
Open-label study noted early improvements in headache intensity and emotional balance during the second week of the 30-day treatment course.
Continued subtle sleep and mild cognitive clarity improvements reported. Effects remain subtle compared to faster-acting peptides (Semax, Selank).
Open-label study (n=48) documented peak improvements in memory, cognitive function, and overall neurological status toward end of the 30-day course. 64.6% of patients showed positive outcomes.
Most community users who report benefit note it primarily in sleep quality and mild cognitive clarity. Effects consistently described as "subtle" compared to Cortexin or Cerebrolysin.
Bioregulator theory holds that epigenetic gene expression changes persist for months after the active dosing period. This is the rationale for the long 3–6 month off-period. Mechanism data exists for related synthetic peptides (Cortagen, Epitalon) but has not been specifically documented for Cerluten's full polypeptide complex.
Insufficient community data to characterize post-course persistence. The long off-period is protocol-derived, not based on documented community observation of sustained benefit.
Source: Estimated from general low-molecular-weight peptide kinetics; no formal PK studies published for Cerluten polypeptide complex
Loading the interactive decay curve.
Cerluten is classified as a dietary supplement (parapharmaceutical) in Russia, manufactured under Khavinson Institute licensing. It is not a registered pharmaceutical drug in any jurisdiction. No FDA approval, clearance, or investigational new drug (IND) application exists for Cerluten in the United States. In the US and EU, Cerluten falls into a regulatory gray area. It can be purchased from Russian pharmacological suppliers (RuPharma, CosmicNootropic) and imported for personal use in small quantities, though import regulations vary by country and can change. It is not available through US pharmacies or compounding pharmacies. Cerluten is not listed on the WADA prohibited substances list, but athletes subject to anti-doping testing should be aware that crude biological extracts carry contamination risk that could trigger a positive result. This content is for educational and research purposes only. Cerluten is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare provider before use, particularly if you take serotonergic medications or have a history of sensitivity to bovine-derived products.
Peptide Schedule Research TeamReviewed Apr 20268 Citations
